Stock price effects of breakthrough therapy designation

被引：4
|
作者：
Hoffmann, David [1 ]
Van Dalsem, Shane [2 ]
David, Frank S. [3 ]
机构：
[1] Inst Mol Biotechnol, Vienna, Austria
[2] Washburn Univ, Sch Business, Topeka, KS 66621 USA
[3] Pharmagellan, Milton, MA 02186 USA
来源：
NATURE REVIEWS DRUG DISCOVERY | 2019年 / 18卷 / 03期
关键词：
Drug discovery;
D O I：
10.1038/d41573-019-00019-6
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
引用
收藏
页码：165 / 165
页数：1
相关论文
共 50 条
  • [21] The Current Status of Sakigake Designation in Japan, PRIME in the European Union, and Breakthrough Therapy Designation in the United States
    Hideyuki Kondo
    Toshiyuki Hata
    Konomi Ito
    Hisashi Koike
    Noriatsu Kono
    Therapeutic Innovation & Regulatory Science, 2017, 51 : 51 - 54
  • [22] The Current Status of Sakigake Designation in Japan, PRIME in the European Union, and Breakthrough Therapy Designation in the United States
    Kondo, Hideyuki
    Hata, Toshiyuki
    Ito, Konomi
    Koike, Hisashi
    Kono, Noriatsu
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2017, 51 (01) : 51 - 54
  • [23] Breakthrough Therapy Designation: CDER Analysis of Requests 4 Years Into the Program
    Conrad, Ryan
    Taylor, Kimberly
    Raggio, Miranda
    Harrington, Afi
    Stark, Grace
    Kish, Andrew
    Bertha, Amy
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2017, 51 (04) : 509 - 515
  • [24] Expediting Drug Development - The FDA's New "Breakthrough Therapy" Designation
    Sherman, Rachel E.
    Li, Jun
    Shapley, Stephanie
    Robb, Melissa
    Woodcock, Janet
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (20): : 1877 - 1880
  • [25] Two Meningococcal B vaccines receive FDA, Breakthrough Therapy' designation
    不详
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (06) : 1428 - 1429
  • [26] FDA breakthrough therapy designation for oncology products: The CBER experience.
    Singh, Harpreet
    Pazdur, Richard
    Xu, Lei
    Liu, Ke
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [27] Pharmacists' Knowledge and Perceptions of FDA Approval Standards and the Breakthrough Therapy Designation
    Herink, Megan C.
    Johnston, Kirbee
    Breninger, Kristin
    Wu, Erin
    Irwin, Adriane N.
    PHARMACY, 2022, 10 (05)
  • [28] Trends in breakthrough therapy designation (vol 14, pg 597, 2015)
    Chizkov, Rachel R.
    Million, Ryan P.
    NATURE REVIEWS DRUG DISCOVERY, 2016, 15 (03) : 216 - 216
  • [29] Trial Design and Efficacy Thresholds for Granting Breakthrough Therapy Designation in Oncology
    Kern, Kenneth A.
    JOURNAL OF ONCOLOGY PRACTICE, 2016, 12 (08) : 733 - +
  • [30] FDA Breakthrough Therapy Designation-Trial Design and More - Commentary
    Corrigan-Curay, Jacqueline
    Stein, Peter
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2021, 110 (04) : 869 - 870
12345